Related Experiment Video

Updated: May 25, 2026

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock
07:39

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock

Published on: August 16, 2021

Adjuvant early and late cardioprotective therapy: access to the heart

Rabea Hinkel1, Peter Boekstegers, Christian Kupatt

  • 1Medizinische Klinik und Poliklinik I, Klinikum der LMU München, Marchioninistraße 15, Munich, Germany. rabea.hinkel@med.uni-muenchen.de

Cardiovascular Research
|February 10, 2012
PubMed

Insights

Therapeutic strategies targeting lethal reperfusion injury can significantly reduce heart attack damage. This review explores optimal drug delivery methods for treating myocardial infarction and improving recovery after reperfusion.

Area of Science:

  • Cardiovascular Medicine
  • Regenerative Medicine
  • Pharmacology

Background:

  • Coronary heart disease remains a leading cause of mortality in industrialized countries.
  • Myocardial infarction (MI) involves acute coronary occlusion or chronic ischaemic cardiomyopathy.
  • Lethal reperfusion injury exacerbates cardiomyocyte loss even after successful reperfusion therapy.

Purpose of the Study:

  • To review current and future administration techniques for therapeutic agents targeting reperfusion injury.
  • To highlight the importance of drug delivery modes in the success of early and late post-MI therapies.
  • To provide insights into optimizing treatment strategies for myocardial infarction.

Main Methods:

  • Literature review of experimental and clinical studies on therapeutic interventions for reperfusion injury.
  • Analysis of various drug administration techniques, including route, timing, and formulation.
  • Evaluation of the impact of delivery methods on infarct size reduction and cardiomyocyte salvage.

Main Results:

  • Experimental studies show that targeted delivery of therapeutic agents can reduce infarct size by up to 30%.
  • The mode of drug application is a critical factor influencing therapeutic efficacy in managing myocardial infarction.
  • Optimized administration techniques are essential for both early and late-stage post-MI treatment.

Conclusions:

  • Effective administration techniques are crucial for maximizing the benefits of therapies aimed at mitigating lethal reperfusion injury.
  • Future research should focus on developing innovative drug delivery systems for improved post-myocardial infarction management.
  • Tailoring administration strategies to specific therapeutic agents and treatment સમયpoints can enhance outcomes for patients with coronary heart disease.

More Related Videos

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine10:05

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine

Published on: July 7, 2016

Percutaneous Contrast Echocardiography-guided Intramyocardial Injection and Cell Delivery in a Large Preclinical Model14:24

Percutaneous Contrast Echocardiography-guided Intramyocardial Injection and Cell Delivery in a Large Preclinical Model

Published on: January 21, 2018

Related Concept Videos

Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...